Shots:  

• XBiotech to receive $750M up front and additional milestones upon certain commercialization authorizations. Janssen to get all rights for bermekimab and will conduct clinical program following the completion of ongoing P-II studies
•  The focus of the acquisition is to fortify Janssen’s expertise in immuno-dermatology while expanding to AD and Hidradenitis Suppurativa (HS) targeting unmet medical needs. Additionally- Janssen has the rights to expand the indication of bermekimab beyond dermatology
• Bermekimab is an investigational mAb targeting IL-1a- currently being evaluated in P-II study for AD and HS/ acne inversa

Click here to­ read full press release/ article 

Ref: Janssen | Image: Janssen